Get Started

BMEA

NASD Biomea Fusion Inc
Oct 29, 2026 · 11:29 PM ET EOD Market Closed

$0.6228 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.6228, $0.0372 below the day’s high of $0.6600

YTD change
-49.77%
vs 20-day SMA
-36.97%
vs 200-day SMA
-54.94%

Price ranges

Previous day
$0.6223 $0.6599
open $0.6500 close $0.6477
-$0.0023 (-0.35%)
Today
$0.6200 $0.6600
open $0.6333 now $0.6228
-$0.0105 (-1.66%)
Past week
$0.5522 $0.7000
from $0.6901 now $0.6228
-$0.0673 (-9.75%)
Past month
$0.5522 $1.4599
from $1.3300 now $0.6228
-$0.7072 (-53.17%)
This year
$0.5522 $2.2370
from $1.2400 now $0.6228
-$0.6172 (-49.77%)

Price & Performance

-0.83 (-57.05%) / 6M

$0.4694$1.03$1.59$2.15Apr 29Jul 30Oct 29

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 98.6% away from all-time highs of $43.6900
  • BMEA is down 50% since the beginning of the year
  • BMEA is down 55% over the past 12 months
  • BMEA is down 53% over the past 1 month
  • 22% of all BMEA investors are betting against BMEA

BMEA reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -54.5%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.12
Earnings momentum +42.1% Quarterly EPS growth
Quarterly change +42.1%

Valuation

P/E ratio N/A
Enterprise value $12.6M
Beta 1.59

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$35.2M
Debt$877.0
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $45.1M

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $460.73 +1.97%
MRNA Moderna, Inc. $222.76 +4.01%
RVMD Revolution Medicines, Inc. $190.27 +0.82%
ROIV Roivant Sciences Ltd. $37.52 +1.10%
BNTX BioNTech SE Sponsored ADR $89.13 +1.30%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.